PMID: 8943896Dec 1, 1996Paper

A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity

British Journal of Haematology
P MoreauJ L Harousseau

Abstract

We studied the pharmacokinetics and toxicity of 220 mg/m2 melphalan (HDM 220) followed by autologous stem cell transplantation in 16 patients with advanced haematological malignancies. Pharmacokinetic parameters (mean values of steady-state volume of distribution 14.6 l/m2, total body clearance 313 ml/min/m2, elimination half-life 46 min) were the same as those of 140 or 200 mg/m2 melphalan in previous reports. HDM 220 was feasible. Extramedullary toxicity was mainly W.H.O. grade 4 mucositis (13/16 patients). The median duration of 41 d (10, not reached) of thrombocytopenia < 25 x 10(9)/l was long. In multiple myeloma the response rate was 89% in heavily pretreated patients, suggesting that HDM 220 could be considered earlier in the course of the disease as an alternative consolidation therapy.

Citations

Jun 19, 2008·Bone Marrow Transplantation·Sk KumarMa Gertz
Sep 6, 2000·Journal of Internal Medicine·G Gahrton, B Björkstrand
Sep 17, 2015·Pediatric Blood & Cancer·Ehud Even-OrJerry Stein
Feb 2, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Lawrence G LumVoravit Ratanatharathorn
Feb 28, 2007·British Journal of Clinical Pharmacology·Christa E NathJohn W Earl
Jun 25, 2010·British Journal of Clinical Pharmacology·Christa E NathJohn Earl
Nov 21, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Enric CarrerasUNKNOWN Spanish Myeloma Group/PETHEMA
Jun 19, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·G L PhillipsN Flomenberg
Jul 27, 2015·Biosensors & Bioelectronics·Ambareesh Kumar Singh, Meenakshi Singh
Dec 3, 2003·Bone Marrow Transplantation·Y Nieto, W P Vaughan
Aug 19, 2014·Bone Marrow Transplantation·P J ShawH M Lazarus
Oct 19, 2000·Anti-cancer Drugs·A D HuitemaJ H Beijnen
Jun 12, 2020·Bone Marrow Transplantation·Deepesh P LadPankaj Malhotra
Feb 15, 2021·The Journal of Applied Laboratory Medicine·Junfang ZhaoKenneth D R Setchell

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.